^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    surzebiclimab (BGB-A425)

    i
    Other names: BGB-A425, BGBA425, BGB A425
    Associations

    News

    Trials
    Company:
    BeOne Medicines
    Drug class:
    TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    BGB-HNSCC-201: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, BeiGene | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Jan 2027 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    9ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=430, Enrolling by invitation, BeiGene | N=300 --> 430
    Enrollment change
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    10ms
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=114, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    11ms
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=114, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=358 --> 114
    Enrollment closed • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    1year
    BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    1year
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, BeiGene | Trial completion date: Dec 2027 --> Apr 2025 | Trial primary completion date: Mar 2026 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    over1year
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    almost2years
    BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    over2years
    Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    over2years
    Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, BeiGene
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    over3years
    BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=358, Recruiting, BeiGene | N=162 --> 358 | Trial completion date: Jan 2024 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Mar 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    4years
    Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=162, Recruiting, BeiGene | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Mar 2023 --> Jul 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • surzebiclimab (BGB-A425)